Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CD117-shielded Cell,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Prime Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : CD117-shielded Cell,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Prime Medicine
Deal Size : Undisclosed
Deal Type : Collaboration